Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more dramatic weight loss in clinical trials, with some participants losing over 25% of their body weight
Below are the details on how orforglipron is compared to Rybelsus, the only oral GLP-1 approved for treating diabetes
Retatrutide works as a powerful triple-agonist, meaning it works on on three key hormone receptors: The human glucagon receptor (GCGR) The glucose-dependent polypeptide receptor (GIP receptor) The glucagon-like peptide-1 receptor (GLP-1) This unique receptor profile allows retatrutide to effectively: Regulate appetite, feelings of fullness, and gastric emptying Regulate metabolism Regulate blood sugar levels The activation of the GIP, GLP-1, and GCG receptors simultaneously by retatrutide leads to better weight loss and cardiometabolic benefits compared to targeting a single receptor
Retatrutide, the newest type of weight-loss drug, helped people lose an average of 70 pounds or about 30% of their body weight over 80 weeks, according to study data from the drugs manufacturer
S7 Plant-Based Antioxidant Blend (50mg): Green Coffee, Green Tea, Turmeric, Tart Cherry, Blueberry, Broccoli & Kale supports nitric oxide production and cellular oxygen flow
Neither is virtual care
